Physician profile
Uma Yadagiri
NPI 1154381630
$5,450.00
in general payments reported to CMS, 2019-2025
27 companies · $21.94 in 2025
The $21.94 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,888 · 2020: $1,087 · 2021: $1,136 · 2022: $1,042 · 2023: $186 · 2024: $89.40 · 2025: $21.94.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $298.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $297.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $687.04 | 2019-2022 | |
| Abbvie INC. | $671.07 | 2021-2025 | Ubrelvy, Vraylar |
| Novo Nordisk INC | $563.15 | 2019-2022 | |
| Lilly USA, LLC | $562.10 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $477.35 | 2019-2022 | |
| Amarin Pharma, INC. | $425.18 | 2019-2022 | |
| Pfizer INC. | $290.34 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $268.34 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $266.85 | 2019-2021 | |
| Daiichi Sankyo INC. | $225.02 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $221.04 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $166.01 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $125.04 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $124.66 | 2023 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $81.64 | 2019-2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $74.56 | 2022 | |
| Allergan, INC. | $35.47 | 2019-2020 | |
| Vertical Pharmaceuticals, LLC | $25.75 | 2019 | |
| Eisai INC. | $25.23 | 2020-2021 | |
| Kowa Pharmaceuticals America, INC. | $24.49 | 2020 | |
| Sanofi-Aventis U.S. LLC | $18.55 | 2020 | |
| Janssen Pharmaceuticals, INC | $17.59 | 2019 | |
| Amgen INC. | $16.53 | 2022 | |
| Ironshore Pharmaceuticals INC. | $16.05 | 2020 | |
| Currax Pharmaceuticals LLC | $15.57 | 2021 | |
| Xeris Pharmaceuticals, INC. | $13.36 | 2024 | Keveyis |
| Nestle Healthcare Nutrition INC. | $12.02 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Uma Yadagiri listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.